BioInvent International AB (publ)
Other OTCTotal Valuation
BioInvent International AB (publ) carries a market capitalization of 216.40M, placing it among publicly traded companies globally. Its enterprise value stands at 1.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 216.40M |
| Enterprise Value | 1.27B |
Share Statistics
BioInvent International AB (publ) currently has 65.80M shares outstanding.
| Shares Outstanding | 65.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 8.09 |
| PB Ratio | N/A |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | -8.51 |
| P/OCF Ratio | -8.27 |
Enterprise Valuation
| EV / Sales | 5.00 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioInvent International AB (publ) maintains a current ratio of 8.59, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.59 |
| Quick Ratio | 7.81 |
| Debt / Equity | 1.60 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -27.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1,822.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, BioInvent International AB (publ) has paid 215,000.00 in income taxes, reflecting an effective tax rate of 0.26.
| Income Tax | 215,000.00 |
| Effective Tax Rate | 0.26 |
Stock Price Statistics
BioInvent International AB (publ)'s stock has declined approximately -30.02979% over the past 52 weeks. The 50-day moving average sits at 3.29, while the 200-day moving average is 3.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.02979% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 3.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioInvent International AB (publ) generated 254.29M in revenue and converted that into -292.03M in net income, yielding earnings per share of -4.44. EBITDA reached -321.88M, while operating income came in at -321.88M.
| Revenue | 254.29M |
| Gross Profit | N/A |
| Operating Income | -321.88M |
| Pretax Income | -291.81M |
| Net Income | -292.03M |
| EBITDA | -321.88M |
| EBIT | -321.88M |
| Earnings Per Share (EPS) | -4.44 |
Balance Sheet
BioInvent International AB (publ) holds 797.52M in cash and equivalents against 12.94M in total debt, resulting in a net debt position of -404.05M.
| Cash & Cash Equivalents | 797.52M |
| Total Debt | 12.94M |
| Net Debt | -404.05M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 774.60M |
Cash Flow
BioInvent International AB (publ) produced -248.58M in operating cash flow over the past twelve months. After subtracting -6.97M in capital expenditures, free cash flow totaled -255.55M - equivalent to -3.89 per share.
| Operating Cash Flow | -248.58M |
| Capital Expenditures | -6.97M |
| Free Cash Flow | -255.55M |
| FCF Per Share | -3.89 |
Margins
BioInvent International AB (publ) operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -126.58 and net profit margin of -114.84 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -126.58 |
| Pretax Margin | -114.76 |
| Profit Margin | -114.84 |
| EBITDA Margin | -126.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.43 |
| FCF Yield | -11.75 |
Stock Splits
BioInvent International AB (publ)'s most recent stock split took place on December 14, 2020 with a 25:1 split ratio.
| Last Split Date | 12/14/2020 |
| Split Ratio | 25:1 |
Scores
BioInvent International AB (publ) posts an Altman Z-Score of 11.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.78 |